![]() Fall 2021University of Alberta Division of Pediatric Emergency Medicine: Providing a vision, guidance, and leadership for high quality research within the Division of Pediatric Emergency Medicine Welcome to the Fall 2021 edition of the Pediatric Emergency Medicine Research Newsletter! This newsletter serves as an update on the activities of the Division of Pediatric Emergency Medicine at the University of Alberta and provides resources and information that may be of interest to readers. Questions? Comments? Contact us at pemres@ualberta.ca ![]() COVID-19 UpdateUpdate: The Pediatric Emergency Medicine research team has been diligent in adhering to Alberta Health Services (AHS) and University of Alberta Environment Health Services (EHS) guidelines to ensure the safety of staff and participants while conducting research during COVID-19 times. We continue to be in close communication with the University of Alberta Public Health Response Team and Stollery Children’s Hospital Emergency Department AHS administration team to assess the ever-changing COVID-19 situation and to make sure our research team is continuing to meet all public health safety requirements under the current provincial restrictions. Resumption of Research Study: BIPED We are excited to resume recruitment for the BIPED study: A Randomized controlled Trial Comparing Epinephrine and Dexamethasone to Placebo in Treatment of Infants with Bronchiolitis. Recruitment for this study was put on hold in March 2020 in adherence of COVID-19 restrictions and concerns around aerosol generating procedures. The study now allows for the use of MDIs and has resumed recruitment as of July 2021. The Principal Investigator for this project is Dr. Amy Plint from Children's Hospital of Eastern Ontario Research Institute and the local site Principal Investigator is Dr. Andrew Dixon. The aim of the study is to determine if treatment of infants presengin with bronchiolitis to the emergency department with inhaled epinephrine and a 2-day course of oral daxamethasone is effective in reducing the need for future admissions to hospital (due to bronchiolitis). Our current COVID-related studies are as follows: Predicting severe pneumonia in the emergency department: a global study of the pediatric emergency research networks (COVID-19 arm): The purpose of this research study arm is to create tools to identify which children are most likely to be infected with SARS-CoV-2, and of these, which children might deteriorate and become sicker following their emergency department visit. Recruitment has completed and together, the team has recruited over 10,000 children across 10 countries. PERC COVID-19 study: The aim of this multi-site study is to understand pediatric ED physicians' perspectives on providing patient care during a pandemic and how it affects their interactions. The Principal Investigator of this project is Dr. Nathalie Gaucher from the Université de Montréal, and the local site Principal Investigator is Dr. Samina Ali, with Manasi Rajagopal also working on this team. Focus group interviews conducted with emergency healthcare providers from 8 emergency departments across Canada were conducted at three phases during the pandemic. The survey conducted as part of this study and the results of the qualitative interviews were presented at this year's Pediatric Emergency Research Canada annual meeting. Manuscripts on the survey and qualitative analyses have also been submitted for publication. A follow-up study with healthcare professionals is currently being planned. ![]() PEM Program UpdatesPEM Team UpdatesEffective July 2021, we announce that Dr. William Craig has stepped down from his role as the Research Director for the Pediatric Emergency Medicine Research Program. Dr. Craig has served as the Research Director for the past 8 years and our program has benefited from his strong vision for improving pediatric emergency medicine research and his leadership. He will continue with his clinical, teaching and research activities with the program. Taking over as the Research Director, Pediatric Emergency Medicine is Dr. Samina Ali. ![]() Fall 2021 HighlightsHighlight: Ongoing PEM StudyKetodex Trial: Intranasal dexmedetomidine plus ketamine for procedural sedation in children: an adaptive randomized controlled non-inferiority multicenter trial Orthopedic injuries comprise more than 10% of ED visits in children and 25 to 50% of children will sustain a fracture before age 16 years. Forearm fractures account for 20-32% of fractures in children, making them the most common fracture type. Between 20 and 40% of extremity fractures in children require a closed reduction, often necessitating procedural sedation and analgesia (PSA). Intravenous (IV) ketamine is the most commonly used sedative agent used to perform a closed reduction. However, children rate IV insertion as the most painful hospital experience, second only to the injury itself. IV insertion can be more technically difficult in children because of smaller veins and lack of cooperation, often leading to multiple IV attempts. A combination of intranasal (IN) dexmedetomidine plus IN ketamine (Ketodex) may provide effective sedation for children undergoing a closed reduction without the distress and pain related to IV insertion. A less painful experience has been found to correlate with child satisfaction which may reduce caregiver anxiety and improve the therapeutic relationship with the health care team. This study is a multi-centre, four-arm, adaptive, randomized, blinded, controlled, non-inferiority trial designed to test the hypothesis that IN Ketodex is non-inferior to intravenous (IV) ketamine with respect to depth of sedation as measured using the Pediatric Sedation State Scale (PSSS). Dr. Naveen Poonai is the national PI for this project, and Dr. Samina Ali is the site lead at the Stollery. Featured PEM Research Team Member: |